An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped?

Cassava Sciences has faced a barrage of regulator scrutiny over alleged clinical impropriety in studies of an experimental Alzheimer’s candidate. Most recently, Cassava shelled out millions to fend off corporate misconduct allegations from the U.S. Securities and Exchange Commission.